Research ArticleHuman Studies
Phase II Scintigraphic Clinical Trial of Malignant Melanoma and Metastases with Iodine-123-N-(2-Diethylaminoethyl 4-Iodobenzamide)
J.M. Michelot, M.F.C. Moreau, A.J. Veyre, J.F. Bonafous, F.J. Bacin, J.C. Madelmont, F. Bussiere, P.A. Souteyrand, L.P. Mauclaire, F.M. Chossat, J.M. Papon, P.G. Labarre, Ph. Kauffmann and R.J. Plagne
Journal of Nuclear Medicine August 1993, 34 (8) 1260-1266;
J.M. Michelot
M.F.C. Moreau
A.J. Veyre
J.F. Bonafous
F.J. Bacin
J.C. Madelmont
F. Bussiere
P.A. Souteyrand
L.P. Mauclaire
F.M. Chossat
J.M. Papon
P.G. Labarre
Ph. Kauffmann
![Loading Loading](https://jnm.snmjournals.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
![PDF extract preview](https://jnm.snmjournals.org/content/34/8/1260.extract.jpg)
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Phase II Scintigraphic Clinical Trial of Malignant Melanoma and Metastases with Iodine-123-N-(2-Diethylaminoethyl 4-Iodobenzamide)
J.M. Michelot, M.F.C. Moreau, A.J. Veyre, J.F. Bonafous, F.J. Bacin, J.C. Madelmont, F. Bussiere, P.A. Souteyrand, L.P. Mauclaire, F.M. Chossat, J.M. Papon, P.G. Labarre, Ph. Kauffmann, R.J. Plagne
Journal of Nuclear Medicine Aug 1993, 34 (8) 1260-1266;
Phase II Scintigraphic Clinical Trial of Malignant Melanoma and Metastases with Iodine-123-N-(2-Diethylaminoethyl 4-Iodobenzamide)
J.M. Michelot, M.F.C. Moreau, A.J. Veyre, J.F. Bonafous, F.J. Bacin, J.C. Madelmont, F. Bussiere, P.A. Souteyrand, L.P. Mauclaire, F.M. Chossat, J.M. Papon, P.G. Labarre, Ph. Kauffmann, R.J. Plagne
Journal of Nuclear Medicine Aug 1993, 34 (8) 1260-1266;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Ultrasensitive detection of malignant melanoma using PET molecular imaging probes
- N-(2-(Dimethylamino)Ethyl)-4-18F-Fluorobenzamide: A Novel Molecular Probe for High-Contrast PET Imaging of Malignant Melanoma
- 123I-BZA2 as a Melanin-Targeted Radiotracer for the Identification of Melanoma Metastases: Results and Perspectives of a Multicenter Phase III Clinical Trial
- Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52
- Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma
- High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance
- Melanin-Targeted Preclinical PET Imaging of Melanoma Metastasis
- A New O6-Alkylguanine-DNA Alkyltransferase Inhibitor Associated with a Nitrosourea (Cystemustine) Validates a Strategy of Melanoma-Targeted Therapy in Murine B16 and Human-Resistant M4Beu Melanoma Xenograft Models
- Preparation and Biologic Evaluation of a Novel Radioiodinated Benzylpiperazine, 123I-MEL037, for Malignant Melanoma
- Secondary Ion Mass Spectrometry as a Tool for Investigating Radiopharmaceutical Distribution at the Cellular Level: The Example of I-BZA and 14C-I-BZA
- [99mTcOAADT]-(CH2)2-NEt2: A Potential Small-Molecule Single-Photon Emission Computed Tomography Probe for Imaging Metastatic Melanoma